


SensiScreen[®] FFPE

CANCER DIAGNOSTICS

Multi-functionality no longer compromises quality. The SensiScreen[®] assay combines simplex and multiplex capabilities with high sensitivity to provide patients with the most suitable treatment suggestion.



SensiScreen[®] FFPE uses efficient and validated methods to analyse somatic mutations within cancer patients. The assay can detect down to 0.25 percent of human genomic DNA in solid biopsies, which underlines its sensitivity. With such capabilities, it provides precise, personalised treatment options that strives for optimal patient care and monitoring.

Result in less than three hours

LoD down to 0.25 percent of a copy

Available as simplex or multiplex

Fresh, frozen or FFPE biopsies

Version 1.0

PRODUCT INFORMATION OF SensiScreen® FFPE

Formats

Ready-To-Use
Dispense Ready

Result Time

Less than three hours

Shipment

≤ 20°C or on dry ice

Loci

V-raf, EGFR, BRAF, KRAS, PIK3CA,
NRAS, and KIT

Reagents and Materials

DNA oligomers modified with
fluorophores, quenchers, and
proprietary PentaBases

Approved Instruments

BaseTyper™ 48
Rotor-Gene (Qiagen)
MX3000P/3005P (Agilent)
LightCycler® 96 + 480 (Roche)
CFX96™ (Bio-Rad)
ABI 7500/7900HT (Applied
Biosystems)
MIC (Bio Molecular Systems)

Configuration
Simplex and multiplex

Design
Reference Assay
Mutation Assay

Storage
Range between -20°C and -80°C

Content
Ready-To-Use: 12 or 60
Dispense Ready: 20 or 50

Detection Sensitivity
0.25-1 % mutation in a 50 ng wild type
background

Equipment Required
Template DNA (extracted patient
gDNA)
Real-Time PCR instrument
Other relevant products
(for more information visit www.pentabase.com)